In 2020, Liu et al. verified the specific highly active deubiquitinase ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1) as a candidate oncoprotein in the aggressive BC patient serum and BC-cell ﻿conditioned media (CM) by deubiquitinase activity profile88. Here, UCHL1 is linked to breast cancer.